# CVRx, Inc.: financial statements, quarterly

CVRX · Nasdaq · CIK 1235912 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/cvrx.md) · [Financials](/companies/cvrx/financials.md) · [Filings](/companies/cvrx/filings.md) · [Insiders](/companies/cvrx/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/cvrx/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [10.5](/filings/0001558370-24-014078.md) | [11.3 d](/filings/0001558370-25-001055.md) | [10.8](/filings/0001558370-25-007077.md) | [11.8](/filings/0001558370-25-010186.md) | [13.4](/filings/0001104659-25-107378.md) | [15.3 d](/filings/0001104659-26-014708.md) | [12.3](/filings/0001104659-26-059023.md) | [13.6](/filings/0001628280-26-054336.md) | [14.7](/filings/0001104659-25-107378.md) | [16.0 d](/filings/0001104659-26-014708.md) | [14.8](/filings/0001104659-26-059023.md) | [15.7](/filings/0001628280-26-054336.md) |
| Cost of revenue | $m | [1.7](/filings/0001558370-24-014078.md) | [1.7 d](/filings/0001558370-25-001055.md) | [1.6](/filings/0001558370-25-007077.md) | [1.9](/filings/0001558370-25-010186.md) | [2.2](/filings/0001104659-25-107378.md) | [2.6 d](/filings/0001104659-26-014708.md) | [2.0](/filings/0001104659-26-059023.md) | [2.1](/filings/0001628280-26-054336.md) | [1.9](/filings/0001104659-25-107378.md) | [2.2 d](/filings/0001104659-26-014708.md) | [1.9](/filings/0001104659-26-059023.md) | [2.0](/filings/0001628280-26-054336.md) |
| Gross profit | $m | [8.8](/filings/0001558370-24-014078.md) | [9.6 d](/filings/0001558370-25-001055.md) | [9.2](/filings/0001558370-25-007077.md) | [9.9](/filings/0001558370-25-010186.md) | [11.1](/filings/0001104659-25-107378.md) | [12.8 d](/filings/0001104659-26-014708.md) | [10.3](/filings/0001104659-26-059023.md) | [11.5](/filings/0001628280-26-054336.md) | [12.8](/filings/0001104659-25-107378.md) | [13.8 d](/filings/0001104659-26-014708.md) | [12.9](/filings/0001104659-26-059023.md) | [13.7](/filings/0001628280-26-054336.md) |
| Research and development | $m | [2.7](/filings/0001558370-24-014078.md) | [2.2 d](/filings/0001558370-25-001055.md) | [3.1](/filings/0001558370-25-007077.md) | [2.8](/filings/0001558370-25-010186.md) | [2.5](/filings/0001104659-25-107378.md) | [2.8 d](/filings/0001104659-26-014708.md) | [2.5](/filings/0001104659-26-059023.md) | [2.5](/filings/0001628280-26-054336.md) | [3.1](/filings/0001104659-25-107378.md) | [3.0 d](/filings/0001104659-26-014708.md) | [3.1](/filings/0001104659-26-059023.md) | [3.1](/filings/0001628280-26-054336.md) |
| Selling, general and administrative | $m | [15.7](/filings/0001558370-24-014078.md) | [17.0 d](/filings/0001558370-25-001055.md) | [28.3](/filings/0001558370-25-007077.md) | [21.1](/filings/0001558370-25-010186.md) | [21.6](/filings/0001104659-25-107378.md) | [20.2 d](/filings/0001104659-26-014708.md) | [21.2](/filings/0001104659-26-059023.md) | [23.4](/filings/0001628280-26-054336.md) | [21.9](/filings/0001104659-25-107378.md) | [22.0 d](/filings/0001104659-26-014708.md) | [22.0](/filings/0001104659-26-059023.md) | [23.6](/filings/0001628280-26-054336.md) |
| Operating income | $m | [(9.5)](/filings/0001558370-24-014078.md) | [(9.7) d](/filings/0001558370-25-001055.md) | [(22.2)](/filings/0001558370-25-007077.md) | [(14.0)](/filings/0001558370-25-010186.md) | [(13.0)](/filings/0001104659-25-107378.md) | [(10.3) d](/filings/0001104659-26-014708.md) | [(13.4)](/filings/0001104659-26-059023.md) | [(14.4)](/filings/0001628280-26-054336.md) | [(12.3)](/filings/0001104659-25-107378.md) | [(11.2) d](/filings/0001104659-26-014708.md) | [(12.2)](/filings/0001104659-26-059023.md) | [(13.0)](/filings/0001628280-26-054336.md) |
| Interest expense | $m | [0.5](/filings/0001558370-23-017121.md) | [0.6 d](/filings/0001558370-24-000932.md) | [1.0](/filings/0001558370-24-007786.md) | [1.0](/filings/0001558370-25-010186.md) | [1.0](/filings/0001104659-25-107378.md) | [1.5 d](/filings/0001104659-26-014708.md) | [1.5](/filings/0001104659-26-059023.md) | [1.5](/filings/0001628280-26-054336.md) | [1.5](/filings/0001104659-25-107378.md) | [1.4 d](/filings/0001104659-26-014708.md) | [1.6](/filings/0001104659-26-059023.md) | [1.6](/filings/0001628280-26-054336.md) |
| Income tax | $m | [0.0](/filings/0001558370-24-014078.md) | [0.0 d](/filings/0001558370-25-001055.md) | [0.0](/filings/0001558370-25-007077.md) | [0.0](/filings/0001558370-25-010186.md) | [0.0](/filings/0001104659-25-107378.md) | [(0.1) d](/filings/0001104659-26-014708.md) | [(0.0)](/filings/0001104659-26-059023.md) | [(0.0)](/filings/0001628280-26-054336.md) | [(0.0)](/filings/0001104659-25-107378.md) | [(0.0) d](/filings/0001104659-26-014708.md) | [0.0](/filings/0001104659-26-059023.md) | [0.0](/filings/0001628280-26-054336.md) |
| Net income | $m | [(9.0)](/filings/0001558370-24-014078.md) | [(9.2) d](/filings/0001558370-25-001055.md) | [(22.2)](/filings/0001558370-25-007077.md) | [(14.0)](/filings/0001558370-25-010186.md) | [(13.1)](/filings/0001104659-25-107378.md) | [(10.7) d](/filings/0001104659-26-014708.md) | [(13.8)](/filings/0001104659-26-059023.md) | [(14.7)](/filings/0001628280-26-054336.md) | [(12.9)](/filings/0001104659-25-107378.md) | [(11.9) d](/filings/0001104659-26-014708.md) | [(13.1)](/filings/0001104659-26-059023.md) | [(14.0)](/filings/0001628280-26-054336.md) |
| Diluted EPS | $ per share | [(0.43)](/filings/0001558370-24-014078.md) | not reported | [(1.04)](/filings/0001558370-25-007077.md) | [(0.65)](/filings/0001558370-25-010186.md) | [(0.57)](/filings/0001104659-25-107378.md) | not reported | [(0.53)](/filings/0001104659-26-059023.md) | [(0.57)](/filings/0001628280-26-054336.md) | [(0.49)](/filings/0001104659-25-107378.md) | not reported | [(0.50)](/filings/0001104659-26-059023.md) | [(0.53)](/filings/0001628280-26-054336.md) |
| Basic EPS | $ per share | [(0.43)](/filings/0001558370-24-014078.md) | not reported | [(1.04)](/filings/0001558370-25-007077.md) | [(0.65)](/filings/0001558370-25-010186.md) | [(0.57)](/filings/0001104659-25-107378.md) | not reported | [(0.53)](/filings/0001104659-26-059023.md) | [(0.57)](/filings/0001628280-26-054336.md) | [(0.49)](/filings/0001104659-25-107378.md) | not reported | [(0.50)](/filings/0001104659-26-059023.md) | [(0.53)](/filings/0001628280-26-054336.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [83.0](/filings/0001558370-23-017121.md) | [90.6](/filings/0001558370-25-001055.md) | [80.1](/filings/0001558370-24-007786.md) | [70.4](/filings/0001558370-24-010719.md) | [100](/filings/0001558370-24-014078.md) | [106](/filings/0001104659-26-014708.md) | [103](/filings/0001558370-25-007077.md) | [95.0](/filings/0001558370-25-010186.md) | [85.1](/filings/0001104659-25-107378.md) | [75.7](/filings/0001628280-26-054336.md) | [72.3](/filings/0001104659-26-059023.md) | [64.6](/filings/0001628280-26-054336.md) |
| Current assets | $m | [104](/filings/0001558370-23-017121.md) | [112](/filings/0001558370-25-001055.md) | [102](/filings/0001558370-24-007786.md) | [92.0](/filings/0001558370-24-010719.md) | [124](/filings/0001558370-24-014078.md) | [130](/filings/0001104659-26-014708.md) | [126](/filings/0001558370-25-007077.md) | [116](/filings/0001558370-25-010186.md) | [108](/filings/0001104659-25-107378.md) | [102](/filings/0001628280-26-054336.md) | [96.8](/filings/0001104659-26-059023.md) | [89.5](/filings/0001628280-26-054336.md) |
| Total assets | $m | [106](/filings/0001558370-23-017121.md) | [115](/filings/0001558370-25-001055.md) | [106](/filings/0001558370-24-007786.md) | [96.0](/filings/0001558370-24-010719.md) | [128](/filings/0001558370-24-014078.md) | [133](/filings/0001104659-26-014708.md) | [130](/filings/0001558370-25-007077.md) | [120](/filings/0001558370-25-010186.md) | [111](/filings/0001104659-25-107378.md) | [105](/filings/0001628280-26-054336.md) | [99.7](/filings/0001104659-26-059023.md) | [92.3](/filings/0001628280-26-054336.md) |
| Current liabilities | $m | [7.4](/filings/0001558370-23-017121.md) | [7.9](/filings/0001558370-25-001055.md) | [8.4](/filings/0001558370-24-007786.md) | [9.1](/filings/0001558370-24-010719.md) | [10.9](/filings/0001558370-24-014078.md) | [10.8](/filings/0001104659-26-014708.md) | [8.5](/filings/0001558370-25-007077.md) | [9.7](/filings/0001558370-25-010186.md) | [11.2](/filings/0001104659-25-107378.md) | [13.3](/filings/0001628280-26-054336.md) | [9.5](/filings/0001104659-26-059023.md) | [11.1](/filings/0001628280-26-054336.md) |
| Total liabilities | $m | [23.6](/filings/0001558370-23-017121.md) | [39.3](/filings/0001558370-25-001055.md) | [39.9](/filings/0001558370-24-007786.md) | [40.7](/filings/0001558370-24-010719.md) | [62.5](/filings/0001558370-24-014078.md) | [62.4](/filings/0001104659-26-014708.md) | [60.2](/filings/0001558370-25-007077.md) | [61.6](/filings/0001558370-25-010186.md) | [63.3](/filings/0001104659-25-107378.md) | [65.5](/filings/0001628280-26-054336.md) | [70.6](/filings/0001104659-26-059023.md) | [72.3](/filings/0001628280-26-054336.md) |
| Long-term debt | $m | [14.3](/filings/0001558370-23-017121.md) | [29.2](/filings/0001558370-25-001055.md) | [29.3](/filings/0001558370-24-007786.md) | [29.3](/filings/0001558370-24-010719.md) | [49.2](/filings/0001558370-24-014078.md) | [49.3](/filings/0001104659-26-014708.md) | [49.3](/filings/0001558370-25-007077.md) | [49.4](/filings/0001558370-25-010186.md) | [49.5](/filings/0001104659-25-107378.md) | [49.5](/filings/0001628280-26-054336.md) | [58.5](/filings/0001104659-26-059023.md) | [58.6](/filings/0001628280-26-054336.md) |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [82.8](/filings/0001558370-24-014078.md) | [75.9](/filings/0001104659-26-014708.md) | [66.3](/filings/0001558370-25-010186.md) | [55.2](/filings/0001104659-25-107378.md) | [65.2](/filings/0001104659-25-107378.md) | [71.1](/filings/0001628280-26-054336.md) | [69.4](/filings/0001628280-26-054336.md) | [57.9](/filings/0001628280-26-054336.md) | [48.1](/filings/0001104659-25-107378.md) | [39.3](/filings/0001628280-26-054336.md) | [29.1](/filings/0001628280-26-054336.md) | [20.0](/filings/0001628280-26-054336.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(8.1) d](/filings/0001558370-24-014078.md) | [(7.8) d](/filings/0001558370-25-001055.md) | [(10.9)](/filings/0001558370-25-007077.md) | [(9.8) d](/filings/0001558370-25-010186.md) | [(10.4) d](/filings/0001104659-25-107378.md) | [(8.0) d](/filings/0001104659-26-014708.md) | [(12.8)](/filings/0001104659-26-059023.md) | [(7.9) d](/filings/0001628280-26-054336.md) | [(9.7) d](/filings/0001104659-25-107378.md) | [(9.8) d](/filings/0001104659-26-014708.md) | [(12.2)](/filings/0001104659-26-059023.md) | [(8.8) d](/filings/0001628280-26-054336.md) |
| Capital expenditure | $m | [0.0 d](/filings/0001558370-24-014078.md) | [0.2 d](/filings/0001558370-25-001055.md) | [0.9](/filings/0001558370-25-007077.md) | [0.4 d](/filings/0001558370-25-010186.md) | [0.0 d](/filings/0001104659-25-107378.md) | [0.1 d](/filings/0001104659-26-014708.md) | [0.1](/filings/0001104659-26-059023.md) | [0.1 d](/filings/0001628280-26-054336.md) | [0.3 d](/filings/0001104659-25-107378.md) | [0.1 d](/filings/0001104659-26-014708.md) | [0.1](/filings/0001104659-26-059023.md) | [0.1 d](/filings/0001628280-26-054336.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [20.6](/filings/0001558370-23-017121.md) | [20.7](/filings/0001558370-24-007786.md) | [20.7](/filings/0001558370-24-010719.md) | [20.8](/filings/0001558370-24-014078.md) | [21.2](/filings/0001558370-25-007077.md) | [21.6](/filings/0001558370-25-010186.md) | [22.8](/filings/0001104659-25-107378.md) | [25.9](/filings/0001104659-26-059023.md) | [26.1](/filings/0001628280-26-054336.md) | [26.2](/filings/0001104659-25-107378.md) | [26.4](/filings/0001104659-26-059023.md) | [26.5](/filings/0001628280-26-054336.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 26,641,597 at 2026-07-30, from the cover of the [10-Q filed 2026-08-06](/filings/0001628280-26-054336.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:35 ET. No prices; not investment advice.